Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Total Liabilities (2016 - 2025)

Haemonetics has reported Total Liabilities over the past 16 years, most recently at $1.6 billion for Q4 2025.

  • For Q4 2025, Total Liabilities fell 2.77% year-over-year to $1.6 billion; the TTM value through Dec 2025 reached $1.6 billion, down 2.77%, while the annual FY2025 figure was $1.6 billion, 31.93% up from the prior year.
  • Total Liabilities for Q4 2025 was $1.6 billion at Haemonetics, down from $1.6 billion in the prior quarter.
  • Over five years, Total Liabilities peaked at $1.6 billion in Q3 2024 and troughed at $1.1 billion in Q3 2022.
  • A 5-year average of $1.3 billion and a median of $1.1 billion in 2022 define the central range for Total Liabilities.
  • On a YoY basis, Total Liabilities climbed as much as 83.77% in 2022 and fell as far as 6.0% in 2022.
  • Year by year, Total Liabilities stood at $1.1 billion in 2021, then fell by 0.08% to $1.1 billion in 2022, then grew by 14.07% to $1.3 billion in 2023, then grew by 29.22% to $1.6 billion in 2024, then decreased by 2.77% to $1.6 billion in 2025.
  • Business Quant data shows Total Liabilities for HAE at $1.6 billion in Q4 2025, $1.6 billion in Q3 2025, and $1.6 billion in Q2 2025.